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Abstract
Background: Multiple infections with diverse enterotoxigenic E. coli (ETEC) strains lead to broad spectrum protection
against ETEC diarrhea. However, the precise mechanism of protection against ETEC infection is still unknown. Therefore,
memory B cell responses and affinity maturation of antibodies to the specific ETEC antigens might be important to
understand the mechanism of protection.
Methodology: In this study, we investigated the heat labile toxin B subunit (LTB) and colonization factor antigens (CFA/I
and CS6) specific IgA and IgG memory B cell responses in Bangladeshi adults (n=52) who were infected with ETEC. We also
investigated the avidity of IgA and IgG antibodies that developed after infection to these antigens.
Principal Findings: Patients infected with ETEC expressing LT or LT+heat stable toxin (ST) and CFA/I group or CS6
colonization factors developed LTB, CFA/I or CS6 specific memory B cell responses at day 30 after infection. Similarly, these
patients developed high avidity IgA and IgG antibodies to LTB, CFA/I or CS6 at day 7 that remained significantly elevated at
day 30 when compared to the avidity of these specific antibodies at the acute stage of infection (day 2). The memory B cell
responses, antibody avidity and other immune responses to CFA/I not only developed in patients infected with ETEC
expressing CFA/I but also in those infected with ETEC expressing CFA/I cross-reacting epitopes. We also detected a
significant positive correlation of LTB, CFA/I and CS6 specific memory B cell responses with the corresponding increase in
antibody avidity.
Conclusion: This study demonstrates that natural infection with ETEC induces memory B cells and high avidity antibodies to
LTB and colonization factor CFA/I and CS6 antigens that could mediate anamnestic responses on re-exposure to ETEC and
may help in understanding the requirements to design an effective vaccination strategies.
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Introduction
Enterotoxigenic Escherichiacoli(ETEC) are one of the major causes
of diarrhea in developing countries, causing approximately 200
million episodes of diarrhea and 380,000 deaths every year [1,2].
ETEC cause diarrhea in children less than 5 years of age in ETEC
endemic areas as well as in adults and travelers to these areas [3,4].
In recent years, ETEC have been shown to be the second most
frequently isolated bacterial pathogens after Vibrio cholerae O1 in
patients with diarrhea in Dhaka, Bangladesh [5]. ETEC strains are
genetically and phenotypically divergent, expressing different toxins
and one or more of several different colonization factors (CFs). The
CFs facilitates the attachment of the bacteria to specific receptors on
the intestinal mucosa [3,6–8]. Production of the heat-stable (ST)
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diarrhea [9]. The LT toxin is a structural homolog and acts in a
similar way as cholera toxin (CT) of V. cholerae, whereas the ST toxin
is a nonimmunogenic small protein molecule [3,9].
Protective immunity against ETEC infection is largely mediated
by immune responses to CFs [10–14]. To date, more than 23
different CFs have been characterized and subdivided into
different groups [3,6,15]. CFs with significant amino acid
sequence similarity and cross-reactive epitopes are grouped
together [6,12]. The colonization factor-I (CFA/I) group is one
of the predominant groups of CFs that has an important role in
pathogenesis of human ETEC. This group includes CFA/I, CS1,
CS2, CS4, CS14, CS17, CS19 and PCFO71 [5,6,16–18]. Human
and animal studies have shown that antibodies to the fimbrial
CFA/I cross-react immunologically with the other CFs of the
CFA/I group [19–21]. Therefore, natural infection or vaccination
with these related CFs might give protection against a wide variety
of ETEC strains expressing CFs with cross-reactive epitopes. The
non-fimbrial colonization factor CS6 has also been found to be
one of the increasingly prevalent CFs present in ETEC strains in
Bangladesh as well as in other ETEC endemic countries [5,22,23].
CS6 is expressed either alone or in association with CS4 or CS5
[6], and can produce both systemic and mucosal antibody
responses following infection in children and adults [22]. CS6
also has been investigated as a vaccine antigen in human and
animal studies using different routes of administration and
formulations of antigen [22,24–26]. Despite these different
evaluations of immunity following ETEC infection and vaccina-
tion, long-term immune responses such as memory B cell
responses and increases in antibody avidity to key ETEC antigens
have not been previously described.
In this study, we have evaluated the generation of memory B
cell responses and increases in antibody avidity to the T cell-
dependent antigens LTB, CFA/I and CS6 following natural
infection with ETEC in adult Bangladeshi individuals. We have
also investigated IgA and IgG antibody responses in plasma, and
circulation of antibody secreting cells (ASC) specific for these
antigens after infection.
Materials and Methods
Study design and subject enrollment
We enrolled 52 adult patients admitted to the International
Centre for Diarrheal Disease Research, Bangladesh (icddr,b)
hospital with acute watery diarrhea between January 2008 and
April 2013. Patients positive for ETEC but negative for V. cholerae
O1 or O139, Shigella, Salmonella and other parasites tested were
included in this study. Blood was collected from the patients at the
time of enrollment (day 2) and again at day 7 and 30 post
infection. At each time point, we assessed antigen (LTB, CFA/I
and CS6)-specific antibody secreting cell (ASC), antibody
responses and avidity of plasma antibodies to these antigens.
Antigen-specific IgG and IgA memory B cell responses were
measured on day 2 and 30.
Ethics statement
Prior to enrollment, written informed consent was obtained
from patients. The study was approved by the Research Review
and Ethical Review Committees of the icddr,b, Dhaka, Bangla-
desh.
Isolation of peripheral blood mononuclear cells (PBMC)
Sodium-heparinized blood was diluted two-fold with phosphate-
buffered saline (PBS, pH 7.2–7.4) and peripheral blood mononu-
clear cells (PBMCs), and plasma samples were isolated after
centrifugation on Ficoll-Isopaque (Pharmacia, Piscataway, NJ)
[27]. Plasma was stored at 220uC for further immunological
assays. PBMCs were washed and resuspended at a concentration
of 10
7 cells/ml in RPMI complete medium (Gibco, Carlsbad, CA)
with 10% heat-inactivated fetal bovine serum (HyClone, Logan,
UT) [27]. The cells were then immediately used for the enzyme-
linked immunosorbent spot (ELISPOT) assay to determine ASC
responses, or cells were cultured for memory B cell responses as
described below.
Detection of LTB- and CF-specific antibody responses in
plasma
CFA/I-, CS6- and LTB-specific IgA and IgG responses in plasma
were assessed by using standardized enzyme-linked immunosorbent
assay (ELISA) technique as described previously [28]. Briefly, 96-
well polystyrene plates (Nunc F, Denmark) were coated with GM1
ganglioside (0.3 nM; University of Gothenburg, Sweden) overnight
followed by recombinant cholera toxin B subunit (CTB) (0.5 mg/ml;
University of Gothenburg, Sweden), or with ETEC colonization
factors CFA/I (University of Gothenburg) or CS6 (1 mg/ml; gift
fromF Cassels,WalterReed ArmyInstitute of Research, Maryland).
LTB has 80% nucleotide sequence similarity to CTB, and cross-
reacts immunologically with CTB [15,29]. Therefore, we used CTB
as the antigen to detect responses to LTB. For detecting each
antigen-specific antibody, 150 ml/well of plasma (initially diluted in
0.1% bovine serum albumin [BSA] in PBS- 0.05%Tween; 1:100 for
LTB and 1:10 for CFA/I and CS6) were added, serially 3-fold
diluted. The presence of antigen-specific antibodies were detected
using horseradish peroxidase (HRP)-conjugated anti-human IgA
and IgG, (Jackson ImmunoResearch, West Grove, PA; 1:2000
dilution in 0.1% BSA-PBS-Tween) and ortho phenylenediamine
(Sigma, St. Louis, MO) in 0.1 M sodium citrate buffer (pH 4.5) and
hydrogen peroxide. The reactions were stopped after 20 minutes by
adding 1 M H2SO4 and endpoint titers were measured as the
reciprocal interpolated dilutions of the samples at 492 nm that were
0.4 above background. ELISA data were normalized by calculating
the ratio of the test sample to a standard of pooled sera derived from
the convalescent phase of ETEC-infected patients used as a positive
control on each plate. These normalized values were multiplied by
100 and defined as ELISA units. Patients with a $2f o l di n c r e a s ei n
the anti-LTB, CFA/I and CS6 antibody responses were considered
as responders.
Author Summary
Enterotoxigenic Escherichia coli (ETEC) is a non-invasive
pathogen causing diarrhea in children as well as in adults
and travelers in developing countries. After colonizing the
intestine using colonization factors, the organisms secrete
heat-stable (ST) and/or heat-labile (LT) enterotoxin to
cause watery diarrhea. Natural infection with ETEC
provides protection against subsequent infection; howev-
er, the precise mechanism is unknown. In this study, we
have shown that adult patients with diarrhea infected with
ETEC develop toxin (LTB) and colonization factor (CFA/I
and CS6) specific memory B cell responses as well as highly
avid antigen-specific antibodies. The antibody avidity
indices were shown to be positively associated with
memory B cell responses, suggesting that these processes
may occur in concert. This study encourages further
evaluation of such responses in children as well as in
vaccinees.
Memory B-cell Responses to ETEC Infection
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CFA/I-, CS6- and LTB- specific IgA and IgG antibody avidity
indices were assessed using previously described methods [30,31].
ELISA was carried out to assess CFA/I-, CS6- and LTB- specific
IgA and IgG antibody responses as described above. After
completion of incubation of the plasma (1:3 to 1:1500 dilution in
0.1% BSA-PBS-Tween) in wells coated with antigens, half of the
total wells were treated with sodium thiocyanate (NaSCN) (2 M
NaSCN in PBS–0.3% Tween), whereas the remaining half of
wells were treated with PBS–0.3% Tween alone for 20 min at
room temperature. Horseradish peroxidase-conjugated anti-
human IgA or IgG antibodies (Jackson Laboratories, Bar Harbor,
ME) were used at a 1:1,000 dilution to determine CFA/I-, CS6-
and LTB-specific IgA or IgG responses, as described above. For
each sample, an OD result between 0.5 to 2.0 in the non-NaSCN
wells was used for the calculation of antibody avidity. The avidity
index was calculated as the ratio of the OD of NaSCN treated
wells to the OD of the untreated wells as described previously
[30,31]. Pooled sera derived from patients in the convalescent
phase of ETEC infection was used as a positive control on each
plate.
Determination of circulating ASC
Antigen-specific IgA and IgG ASC responses were determined
using ELISPOT, as previously described [12,22,32]. Briefly,
nitrocellulose-bottomed plates (MSHAN4550; Millipore, Bed-
ford, MA) were coated with CFA/I (10 mg/ml), CS6 (10 mg/ml),
or GM1 ganglioside (3 nM) followed by recombinant CTB
(2.5 mg/ml). We also coated plates with affinity-purified goat anti-
human immunoglobulin (5 mg/ml; Jackson Immunology Re-
search, West Grove, PA) to measure total IgA and IgG antibody
secreting cells, or with keyhole limpet hemocyanin (KLH,
2.5 mg/ml; Pierce Biotechnology, Rockford, IL) as a negative
control. Antigen-specific ASCs were detected using alkaline
phosphatase-conjugated goat anti-human IgG (Southern Biotech,
Birmingham, AL) and horseradish peroxidase -conjugated IgA
(Southern Biotech, Birmingham, AL), followed by 5-bromo-4-
chloro-3-indolylphosphate–nitroblue tetrazolium (BCIP-NBT;
Sigma, St. Louis, MO) and 3-amino-9-ethyl carbazole (AEC),
respectively. Independent counts visualized by two individuals
using a stereomicroscope (red spots indicating IgA and blue spots
indicating IgG on the same wells) were averaged, and results were
expressed as percentage of antigen-specific ASC out of total ASC
of that isotype.
Memory B cell culture and assay
Memory B cells were assessed on days 2 and 30 by an
ELISPOT technique, as previously described [27,33,34]. Freshly
isolated PBMCs from blood were cultured in 24-well cell culture
plates (BD Biosciences, San Jose, CA) at 5610
5 PBMCs/well in
RPMI 1640 medium containing 10% FBS, 2 mM L-glutamine,
200 units/ml penicillin, 200 mg/ml streptomycin, and 50 mM
beta-mercaptoethanol, along with a mixture of three B-cell
mitogens including CpG oligonucleotide (6 mg/ml; Operon,
Huntsville, AL), a 1/100,000 dilution of crude pokeweed mitogen
extract, and a 1/10,000 dilution of fixed Staphylococcus aureus
Cowan (Sigma, St. Louis, MO). As a negative control, cells were
placed in wells without the mitogen mixture. After incubating the
cells at 37uCw i t h5 %C O 2 for 6 days, cells were harvested and
memory B cell responses were determined by examining for ASC
that had matured under stimulation using an ELISPOT method
as described above. We detected memory B cell responses using
horseradish peroxidase-conjugated mouse anti-human IgA and
IgG (Hybridoma Reagent Laboratory, Baltimore, MD), followed
by AEC. Antigen-specific memory B cell responses were
expressed as the percentage of antigen-specific ELISPOT counts
out of the total isotype-specific Ig-reactive cells. The limits of
detection for responders for antigen-specific IgA and IgG was
defined as 0.004% and 0.001%, respectively, per 5610
5 PBMC
after 6 days of stimulation [27,33]. The inclusion and exclusion
criteria for analyses of data were used as previously described
[35].
Statistical analyses
Statistical analyses were performed using GraphPad Prism 4
(GraphPad Software, Inc., La Jolla, CA). Immunological
responses were compared within groups for significance using
Wilcoxon signed-rank test. We used Spearman’s correlation
analysis to measure bivariate associations. All reported P values
were two tailed and statistical significance was defined as a P
value of #0.05.
Results
Study population
In this study, we enrolled 52 adult (median age 32 years, 48%
female) patients with diarrhea who were infected with ETEC. Of
the patients, 60%, 19% and 21% were infected with LT/ST-, LT-
or ST- expressing ETEC respectively. The majority of the patients
were infected with ETEC expressing either CFA/I group (n=15,
29%) or CS6 with or without CS5 (n=12, 23%) as their
colonization factor. Most of the ETEC strains expressing CFs
cross-reacting with CFA/I, or CS6 with or without CS5, produced
either LT or both LT and ST (73 and 75%, respectively), whereas
all 4 strains expressing CFA/I itself produced ST only. Eighty
seven percent of the patients completed follow up to day 30. The
demographic, clinical and microbiological characteristics are
presented in Table 1.
Table 1. Demographic, clinical and microbiological
characteristics of patients.
Characteristics
Number of study participants 52
Follow up completed to day 30 (%) 45 (87%)
Median age in yr (25
th,7 5
th percentile) 32 (25,40)
Gender, female (%) 25 (48%)
Mean (SD) duration of diarrhea prior to hospitalization, hours 21.66 (18.98)
Mean (SD) duration of hospital stay, hours 32.19 (22.92)
Toxin types of ETEC strains, n (%)
LT/ST 31 (60%)
LT 10 (19%)
ST 11 (21%)
Colonization factors of ETEC strains, n
CFA/I group strains: (CFA/I, CS17, CS4, CS14) 10 (3, 2, 1, 4)
CFA/I group CS1+CS3+CS21, CS2+CS3, CFA/I+CS21 5 (3, 1, 1)
CS6 (CS6 only, CS5+CS6) 12 (6, 6)
CS7 2
CF negative 23
doi:10.1371/journal.pntd.0002822.t001
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(CF) specific antibody responses in plasma
LTB and colonization factor CFA/I or CS6 specific IgA and
IgG antibody responses in plasma were measured at the acute
stage of infection (day 2) and again on days 7 and 30. Statistically
significant increases of IgA and IgG antibody responses to LTB
were observed on day 7 when compared to responses seen at the
acute stage (P,0.0001 for both isotypes) in patients infected with
ETEC expressing LT or LT/ST (Fig. 1A and D). The LTB-IgA
and IgG antibody levels remained elevated up to day 30 compared
to day 2 results (P,0.003 for both isotypes). We did not detect any
response to LTB in patients infected with ETEC expressing ST
alone. CFA/I-specific IgA and IgG antibody responses also
peaked on day 7 in patients infected with ETEC expressing
CFA/I group CFs (P,0.002) (Fig. 1B and E). Of note, patients
infected either with homologous (response rates, 75% for IgG and
100% for IgA) or cross-reacting (response rate, 50% for both IgG
and IgA) CFs responded well with IgG and IgA antibodies to
CFA/I. The IgG responses to CFA/I remained elevated up to day
30 (P=0.004), whereas the IgA responses were short-lived and had
decreased to baseline by day 30. We did not see significant IgA or
IgG antibody responses to CFA/I in patients infected with ETEC
expressing other CFs or no CFs. Similarly, patients infected with
ETEC expressing CS6, with or without CS5, showed significant
increases in CS6 IgA and IgG antibody responses at day 7
(P,0.004) (Fig. 1C and F). Both IgA and IgG antibody levels
remained elevated up to day 30 when compared with day 2
(P,0.02). Responses against CS6 were not observed in patients
infected with ETEC expressing CFs other than CS6.
Heat labile toxin B subunit (LTB) and colonization factor
(CF)-specific antibody avidity in plasma
The mean avidity index (AI) for IgA and IgG antibodies to LTB
at day 2 was 31% and 35%, respectively (Fig. 2A, 2D). These
increased significantly at day 7 (AI=43% and 45%, respectively)
(P,0.003) and remained elevated up to day 30 (AI=39% and
41%, respectively) (P,0.05) in patients infected with ETEC
expressing LT or LT/ST. Significant increases in AI of CFA/I-
specific IgA and IgG antibodies was also observed (Fig. 2B,2E) the
increase in AI was more robust for IgG antibodies than IgA. The
AI remained elevated up to day 30, with AI of 51% and 55%,
respectively (P,0.05). Similarly, patients infected with ETEC
expressing CS6 with or without CS5 developed high avidity IgA
and IgG antibodies to CS6 at day 7 (AI=44% and 55%,
respectively) when compared to day 2 (AI=32% and 42%,
respectively) (P,0.007), (Fig. 2C,2E) and the AI remained elevated
at day 30 (AI=43% and 61%, respectively) for both isotypes of
antibodies (P,0.05).
Antigen specific IgA and IgG ASC responses
LTB, CFA/I and CS6-specific IgA and IgG specific ASC
responses were measured on days 2, 7 and 30. As expected, ASC
responses to all three antigens peaked at day 7 and had waned at
day 30 in patients infected with ETEC expressing LT or LT/ST,
Figure 1. Anti-LTB (A and D), CFA/I (B and E) and CS6 (C and F) specific IgA and IgG antibody responses in plasma in Bangladeshi
adults infected with ETEC. The columns indicate mean responses and the error bars represent standard errors of the mean (SEM). An asterisk
denotes a statistically significant difference (P,0.05) from the acute stage of infection (day 2). Mean fold changes and responder frequencies
compared to day 2 levels are also indicated.
doi:10.1371/journal.pntd.0002822.g001
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Bangladeshi adults infected with ETEC. Columns indicate mean avidity indices, and error bars represent standard errors of the mean (SEM). An
asterisk denotes a statistically significant difference (P,0.05) from the acute stage of infection (day 2).
doi:10.1371/journal.pntd.0002822.g002
Figure 3. Mean + standard errors of the mean (SEM) circulating IgA/total IgA and IgG/total IgG ASC responses to LTB, CFA/I and CS6
in adult Bangladeshi ETEC patients. An asterisk denotes a statistically significant difference (P,0.05) from the acute stage of infection (day 2).
doi:10.1371/journal.pntd.0002822.g003
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observed that the response rate in patients infected with CFA/I
(response rate, 75% for IgA and IgG) or CFA/I cross-reactive CFs
(response rate, 70–80% for IgA and IgG) were comparable.
However, we did not detect such responses in patients infected
with ETEC expressing other or no known CFs.
Antigen-specific memory B cell responses
Memory IgA and IgG B cell responses to LTB, CFA/I and CS6
were measured on days 2 and 30. Significant LTB-specific IgA and
IgG memory B cell responses were observed on day 30 in patients
infected with ETEC expressing LT or LT/ST compared to day 2
(P,0.04) (Fig. 4A and C). Detectable IgA and IgG memory B cell
responses to LTB were found in 41% and 25% of patients at the
acute stage of infection, and that increased to 72% and 48%,
respectively, at day 30 in LT or LT/ST infected patients. However,
we did not detect memory B cell responses to LTB in patients
infected with ST-expressing ETEC. We also measured memory B
cell responses to colonization factors CFA/I and CS6, combining
data from patients infected with ETEC expressing CFA/I group
CFs or CS6 due to paucity of matched paired data for statistical
analyses. We detected a significant increase of CF (CFA/I or CS6)-
specific IgA and IgG memory B cell responses at day 30 when
compared to the memory B cell responsesat day2 (P#0.05) (Fig.4B
and D). Detectable CFs (CFA/I and CS6)-specific IgA and IgG
memory B cell responses were observed in 35% and 21% of
patients, respectively, at day 2, and that increased to 60% and 55%,
respectively, at day 30. CFA/I specific memory B cell responses
were not only observed in CFA/I infected patients, but also in
patients infected with strains expressing cross-reacting CFs.
Detectable CFA/I-specific IgA and IgG memory B cell responses
were found in 50–65% of the patents infected with strains
expressing CFA/I). However, we did not detect CFA/I or
Figure 4. LTB (A and C) and CF (B and D) specific memory B cell responses in patients infected with ETEC. The columns indicate mean
responses and the error bars represent standard errors of the mean. An asterisk denotes a statistically significant difference (P,0.05) from the acute
stage of infection (day 2).
doi:10.1371/journal.pntd.0002822.g004
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negative ETEC or ETEC expressing heterologous CFs.
Correlation between development of antigen-specific
memory B cell responses and increased antibody avidity
To determine potential correlation between development of
antigen-specific memory B cell responses and increased antibody
avidity, we compared LTB, CFA/I and CS6-specific IgA and IgG
memory B cell responses with avidity indices on corresponding
study days in patients infected with ETEC expressing LT or LT/
ST, CFA/I or CS6 antigen, respectively. For all three antigens, we
detected a positive correlation between development of memory B
cell responses and increases of avidity indices of IgA and IgG
antibodies on corresponding study days (Spearman, r=0.32 to
0.6, P=0.003–0.1), although correlation for IgG responses to CS6
did not reach statistical significance and correlation for LTB
specific responses were weak (Spearman, r=0.323 to 0.338,
P=0.026–0.054) (Table 2).
Discussion
In this study, we have shown for the first time the development
of memory B cell responses as well as increased avidity antibodies
to homologous and cross-reacting ETEC antigens in hospitalized
patients with ETEC diarrhea. The development of memory B cells
and high avidity IgA and IgG antibodies to CFA/I or CS6 were
detected in patients infected with CFA/I group or CS6 ETEC,
respectively, but not in patients infected with ETEC expressing
heterologous CFs. LTB specific responses were only observed in
patients infected with ETEC expressing LT or LT/ST, but not
with ST-only expressing ETEC. Similar patterns of ASC and
antibody responses were also observed to CFA/I, CS6 and LTB in
patients infected with homologous or cross-reacting antigens. We
also show that there was a correlation between development of
increased antibody avidity and development of memory B cell
responses to the same antigen on corresponding study days,
suggesting that these responses may occur simultaneously as part
of maturation of B cells and antibody maturation during somatic
hypermutation following antigenic stimulation.
Memory B cells are thought to play a critical role in eliciting a
rapid anamnestic antibody response upon antigen re-exposure, and
thus to play a key role in mediating long-lasting immunity [34,36].
During a primary infection, presence of an antigen at the mucosal
surface generates a cascade of interactions in the germinal center
(GC) of the secondary lymphoid organs [37]. T-cell dependent
protein antigens induce differentiation of CD4+ helper T cells into
follicular helper T cells (TFH) that subsequently interact with B cells
in the GC and stimulate B cell proliferation, somatic hypermuta-
tion, and isotype switching. These events in the GC lead to
generation of memory B cells as well as plasma cells producing
antibodies with increased avidity [37,38], and both of these have
been suggested to play a critical role in protective immunity. We
have shown that in V. cholerae O1 infection, development of memory
B cell responses and high avidity antibodies to T cell dependent
protein antigens develop and persist over the course of a year
following infection [27,30]. Similar measurement of memory B cell
responses and antibody avidity to key protein antigens following
ETEC infection has not previously been reported.
Protective immunity against ETEC is most likely dependent on
mucosal immunity, with secretion of antibodies that prevent
binding of bacteria and/or toxins to mucosal epithelial cells
[39,40]. Human and animal studies have shown that antibodies to
CF antigens provide protection against infection with ETEC
expressing the homologous CFs [11,13,14,41,42]. CFA/I can
prime and boost antibody responses, as well as ASC responses,
against the cross reacting CS4 antigen and vice versa [43]. Adult
Bangladeshi patients infected with CFA/I expressing ETEC also
respond with significant IgA antibody responses to the cross
reactive CS1, CS2, CS4, CS14 and PCFO166 colonization
factors, in addition to the homologous CFA/I antigen [12,21].
This suggests that ETEC can stimulate immune responses to both
homologous and cross reacting CFs. In concordance with the
above findings, we here report that patients infected with ETEC
expressing CFA/I group CFs other than CFA/I develop anti-
CFA/I-IgG and IgA ASC and antibody responses. Moreover,
these patients develop memory B cell responses and highly avid
IgA and IgG antibodies to CFA/I, suggesting that immune
responses against cross-reactive epitopes may be protective. We
have previously shown that mucosal and systemic immune
responses also develop in humans infected with ETEC expressing
CS6, with or without CS4 or CS5 [22], and in recent studies, that
oral immunization of mice with inactivated E. coli bacteria
overexpressing CS6 induces substantial immune responses against
this antigen [25]. In this study, we show that patients infected with
CS6-expressing ETEC not only develop CS6-specific IgG and IgA
ASC and antibody responses, but also memory B cell responses
and highly avid anti-CS6 IgA and IgG antibodies after onset of
diarrhea.
Several human and animal studies have shown that both LT
and CT immunity can provide protection against ETEC strains
expressing LT or LT/ST [26,39]. LT can also act as a mucosal
adjuvant to boost immune responses. In this study, we show the
development of memory B cell responses and high avidity IgA and
IgG antibodies to LTB, responses that may play a role in
immunity following ETEC infection.
The present data on memory B cell responses and antibody
avidity to different ETEC antigens following infection may
provide insights into vaccine development. The multivalent
nature of the antigens expressed by different ETEC strains
makes design of a broadly effective vaccine challenging. Efforts
have been made to develop live attenuated [44] as well as
inactivated whole cell ETEC vaccines expressing high levels of
the most prevalent CFs , i.e. CFA/I, CS1-CS6, which have
the potential to also provide cross-reactive immunity against
ETEC expressing related CFs [25,40,45]. These vaccines have
been tested in human and animals and proven to be safe and
provide strong mucosal immune responses [25,44], (Lundgren
Table 2. Correlation analyses* of antibody avidity index (AI)
and memory B cell (MBC) responses in patients infected with
ETEC.
Correlations between different groups Spearman r P-value
LTB specific
IgG-AI and IgG-MBC 0.338 0.026
IgA-AI and IgA- MBC 0.323 0.054
CFA/I specific
IgG-AI and IgG- MBC 0.437 0.047
IgA-AI and IgA- MBC 0.601 0.003
CS6 specific
IgG-AI and IgG- MBC 0.437 0.103
IgA-AI and IgA- MBC 0.574 0.020
*Spearman’s test was used for correlation analyses.
doi:10.1371/journal.pntd.0002822.t002
Memory B-cell Responses to ETEC Infection
PLOS Neglected Tropical Diseases | www.plosntds.org 7 April 2014 | Volume 8 | Issue 4 | e2822et al, to be published). Similarly, fimbrial tip adhesions are being
evaluated as vaccine candidates against ETEC infection [46].
Further studies of memory B cell responses and antibody avidity
to key antigens after administration of these vaccines will be of
interest.
In summary, our results show that adult patients with ETEC
diarrhea develop toxin (LTB) and colonization factor (CFA/I and
CS6) specific memory B cell responses, as well as highly avid IgG
and IgA antibodies to these same antigens; development of these
immune responses correlates with each other, consistent with the
known pathways of B cell development and maturation. Patients
infected with ETEC expressing the CFA/I group CFs not only
develop immune responses to the homologous CFA/I antigen but
also to cross-reactive CFs, suggesting that such infections may
provide broad spectrum immunity. These findings encourage
further studies to evaluate whether memory B cell responses,
affinity maturation and level of antibodies to these ETEC antigens
correlate with protection following natural infection.
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